MedTrace Logo

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

NCT05300425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2024-12-13

No results posted yet for this study

Summary

Human leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Due to its frequent inapparent course or mild severity with unspecific symptoms and limited availability of diagnostic laboratories the incidence of leptospirosis is likely to be underestimated. The hospital of Val Müstair is the major healthcare provider of a rural mountain valley in the canton of Graubünden/ Switzerland with approximately 1500 inhabitants. A relevant prevalence of Leptospira spp. antibodies in the population of the Val Müstair due to its geographic and social risk profile for Leptospira infection, namely the close contact of the population to both livestock and wildlife in agriculture and hunting is estimated. The aim of this study is to analyze the burden of this disease in order to evaluate the need of preventive measures. In addition, seroepidemiological data for the Hepatitis E virus (HEV) and for tularemia will be collected.

Conditions

  • Leptospirosis
  • Hepatitis E Virus Infection
  • Tularemia

Interventions

OTHER

Blood sample collection

Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).

OTHER

Data collection

Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact

Sponsors & Collaborators

  • Kantonsspital St. Gallen, St. Gallen, Switzerland

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Michael Osthoff, PD Dr. med. · University Hospital Basel, Division of Internal Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2024-11-15
Completion
2024-11-15

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05300425 on ClinicalTrials.gov